Compare Adaptive Biotechnologies Corp (ADPT) vs BlackBerry Limited (BB) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

BlackBerry (BB) trades at $11.10, down 3.56% on the day but remains in a strong uptrend, having more than tripled year-to-date. The stock is technically bullish with recent earnings beats and improved guidance fueling optimism. Revenue growth is returning, with Q1 2026 results showing a profit turnaround, though valuation multiples remain elevated. Positive sentiment is driven by QNX software growth and the launch of leveraged ETFs tied to the stock.

Outlook is cautiously optimistic as execution on QNX and cybersecurity growth must justify high valuations. Key risks include competitive pressures and the need to sustain profitability. Analysts are mostly neutral with a consensus price target of $10.50, suggesting limited near-term upside from current levels amid rich pricing.